Medical/Pharmaceuticals
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy
Australia now open for study of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Oct. 13, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying t...
2022-10-13 22:25
2430
First in North America: Jolly Good Hosts Clinical VR Multi Seminar in Boston, Aiming for Mass Production of UGC Medical VR
At the Boston Convention Center on Tuesday, October 25, 2022 TOKYO, Oct. 13, 2022 /PRNewswire/ -- Jolly Good Inc. (Chuo-ku, Tokyo, CEO: Kensuke Joji, hereinafter referred to as "Jolly Good") will hold a large-scale seminar on clinical training VR produced by the UGC* medical VR platform "JOLLYGO...
2022-10-13 21:00
2249
Research Collaboration between Prof. Antonio Gasbarrini team at Gemelli Hospital and Asian Biotech companies, Coree and Dx&Vx
SEOUL, South Korea, Oct. 13, 2022 /PRNewswire/ -- According to International Diabetes Federation, approximately 537 million adults (20-79 years) are living with diabetes worldwide and 206 million adults of the Western Pacific region includingChina, Japan, and South Korea have diabetes in 2021. St...
2022-10-13 21:00
2248
Neurophth Therapeutics Conducts Special Interview with Dr. Satoshi Kashii on World Sight Day
WUHAN, China and SAN DIEGO, Calif., Oct. 13, 2022 /PRNewswire/ -- October 13th is World Sight Day.Today, Neurophth Therapeutics, Inc. has a special interview with Dr.Satoshi Kashii, Professor of Visual Sciences and Ophthalmology, Aichi Shukutoku University, President of Asian Neuro-Ophthalmology ...
2022-10-13 20:30
3267
Harbour BioMed Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 13, 2022 /PRNewswire/ -- Harbour BioMed (the "Company", HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunol...
2022-10-13 19:05
2302
Samsung Biologics obtains three global ISO certifications
* Receives accreditation for information security management system, information security in cloud services, and anti-bribery management systems * First global CDMO to be ISO 27001 and ISO 27017 certified * Earns Excellence Award for Integrated Management System from BSI for its performance ...
2022-10-13 19:00
2440
Guiyang's Wudang district shines in pharma sector
GUIYANG, Oct. 12, 2022 /PRNewswire/ -- A news report from chinadaily.com.cn: Southwest China's Guizhou province – one of the four main regions for traditional Chinese medicine materials production inChina – has abundant medicine resources and a long history in ethnic medicine, and these days, it...
2022-10-13 10:12
1736
United Imaging Ships Global Installations Number 20,000, 20,001 and 20,002 from its Houston Headquarters to New York City
Fresh off the heels of its recent IPO, the company continues its steady U.S. growth. HOUSTON, Oct. 12, 2022 /PRNewswire/ -- United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment, announced that it is now shipping its 20,000th installation and two additi...
2022-10-12 21:00
2114
Great Bay Bio Announces Official Launch of Site-Specific Integration Platform for Cell Line Development, AlfaCell®
HONG KONG, Oct. 11, 2022 /PRNewswire/ -- Great Bay Bio (hereinafter referred to as "GBB") today announces the official launch of its self-developed AI-enabled site-specific integration platform for cell line development (CLD), AlfaCell®. AlfaCell® platform has pioneered to integrate GBB's proprie...
2022-10-11 20:40
2661
HanAll's Licensed Partner in China Enters Sublicense Agreement with CSPC to Further Accelerate Development of Batoclimab
* Harbour BioMed, HanAll's licensed partner in China, signed a sublicense agreement with CSPC NBP Pharmaceutical for batoclimab, an FcRn compound originally discovered and developed by HanAll Biopharma * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China, ...
2022-10-11 19:00
2119
Samsung Biologics unlocks additional capacity for production at its newest Plant 4
* Plant 4 commences GMP operations within just 23 months since groundbreaking, as planned * Partial operations add fresh biomanufacturing capacity of 60,000 liters * Plant 4's total capacity of 240,000 liters to be ready early next year INCHEON,South Korea, Oct. 11, 2022 /PRNewswire/ -- Sams...
2022-10-11 19:00
2370
IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder
PHILADELPHIA and SAN JOSE, Calif. and NANJING and SHANGHAI, China, Oct. 11, 2022 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company engaged in discovering, developing, and manufacturing innovative medicines and Cabaletta Bio, Inc. (Nasdaq: CABA), a clini...
2022-10-11 19:00
2663
Actinogen Medical Limited (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer's Disease (AD) patients
Clinical Dementia Rating Scale - Sum of Boxes effect of 0.6 to 0.8 points observed in patients with elevated pTau biomarker with once daily, 10 mg, oral therapy SYDNEY, Oct. 10, 2022 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) today announces positive Phase 2a clinical data from its Alz...
2022-10-10 20:00
2555
Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA
* Hugel received CRL from the U.S. FDA last March and completely supplemented documents and data. * It is expected to obtain the U.S. FDA's approval in the first half of 2023 and aims to become a TOP 3 botulinum toxin brand in the U.S. market. SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- ...
2022-10-08 11:00
3130
Antengene Announces Upcoming Presentations at the 2022 Society for Immunotherapy of Cancer Annual Meeting
* Oral presentation highlights preclinical data of ATG-031, an in-house discovered anti-CD24 monoclonal antibody * Three poster presentations showcase preclinical data of ATG-101, a PD-L1/4-1BB bispecific antibody developed in-house, ATG-018, an ATR inhibitor discovered in-house, and ATG-027,...
2022-10-08 10:43
3174
First patient treated in Clarity's therapeutic prostate cancer trial
Highlights * Clarity Pharmaceuticals recruits and treats its first patient in the therapeutic phase of its SAR-bisPSMA theranostic clinical trial SECuRE (NCT04868604)[1] investigating Targeted Copper Theranostics (TCTs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) ...
2022-10-07 21:06
2643
United Imaging Installs Broward County's First uMI 550 at Holy Cross Health in Fort Lauderdale
Holy Cross procured the uMI 550 to "go digital" and continue to innovate for its community. HOUSTON, Oct. 6, 2022 /PRNewswire/ -- United Imaging, a global manufacturer of medical imaging equipment, announced the installation ofBroward County's first uMI 550 at Holy Cross Health, a member of Trin...
2022-10-07 00:00
1945
HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner
* Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402) * In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL cholesterol level * Batoclimab (form...
2022-10-04 19:00
2261
Hayashibara Brings Back "Trehalose Symposium" to Reveal Its Game-changing Versatilities in Human Biochemistry
OKAYAMA, Japan, Oct. 4, 2022 /PRNewswire/ -- Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, westernJapan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, onSeptember 8, 2022. Photo: https://kyodonewsprwir...
2022-10-04 14:00
1762
Duality announced the appointment of Dr. Yver as Chairman of SAB
PRINCETON, N. J. and SHANGHAI, SUZHOU, China, Oct. 3, 2022 /PRNewswire/ -- Duality Biotherapeutics, Inc. ("Duality" or "the Company") today announced the appointment of Dr.Antoine Yver as Chairman of SAB. Dr. Antoine Yver will provide strategic advice and guidance for the Company's R&D and pipeli...
2022-10-03 22:00
2475
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
62639
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
58637
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
55754
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
25227
